Dolutegravir

51 interactions 339 cited references
Also sold as: Juluca® (as a combination product containing dolutegravir, rilpivirine) Tivicay Tivicay® Tivicay® PD
About Dolutegravir

Dolutegravir is used with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 4 weeks of age and older who weigh at least 6.6 lbs (3 kg). It is also used in combination with rilpivirine (Edurant) to treat HIV in certain adults to replace their current HIV medication(s) that ha… Read the full Dolutegravir drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dofetilide Ensitrelvir Abametapir Cabotegravir Dalfampridine Aluminum
2 Contraindicated 45 Major 4 Moderate
All (51) Contraindicated (2) Major (45) Moderate (4)

Contraindicated

Dolutegravir Dofetilide Tikosyn Increased dofetilide exposure and risk of serious or life-threatening events Details Dolutegravir Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details

Major

Dolutegravir Abametapir Increased exposure of CYP3A4 substrate Details Dolutegravir Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Dolutegravir Dalfampridine Ampyra Increased dalfampridine exposure and an increased risk of seizures Details Dolutegravir Aluminum Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Amprenavir Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Dolutegravir Atidarsagene Autotemcel Lenmeldy Interference with the manufacturing of atidarsagene autotemcel Details Dolutegravir Avacopan Tavneos Increased CYP3A4 substrate exposure Details Dolutegravir Calcium Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Carbamazepine Carbatrol Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Dolutegravir Conivaptan Vaprisol Increased CYP3A substrate exposure Details Dolutegravir Dabrafenib Tafinlar Decreased dolutegravir exposure and potential loss of efficacy Details Dolutegravir Dasabuvir Increased dasabuvir and dolutegravir plasma concentrations Details Dolutegravir Efavirenz Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Dolutegravir Eslicarbazepine Acetate Aptiom Decreased dolutegravir exposure and potential loss of efficacy Details Dolutegravir Etravirine Intelence Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Etuvetidigene Autotemcel An increased risk of interference with the manufacturing of etuvetidigene autotemcel Details Dolutegravir Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Dolutegravir Fexinidazole An increased CYP3A4 substrate exposure Details Dolutegravir Fosamprenavir Lexiva Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Fosphenytoin Cerebyx Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Iron Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Dolutegravir Letermovir Prevymis Increased CYP3A substrate exposure Details Dolutegravir Magaldrate Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Magnesium Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Metformin Fortamet® Increased metFORMIN exposure and an increased risk of lactic acidosis Details Dolutegravir Mifepristone Korlym Increased CYP3A4 substrate exposure Details Dolutegravir Nevirapine Viramune Decreased dolutegravir exposure with reduced efficacy Details Dolutegravir Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dolutegravir Oxcarbazepine Oxtellar Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Phenobarbital Fidoquel Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Phenytoin Dilantin Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Primidone Mysoline Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Dolutegravir Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Dolutegravir Rifampin Rifadin Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.